MBL-61
MBL-61, or MOB-61, also known as 1-methyl-2-bromo-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD).
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
MBL-61, or MOB-61, also known as 1-methyl-2-bromo-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD). It is the 1-methyl derivative of 2-bromo-LSD (BOL-148).
Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide (1-methylmethylergometrine) conversion into methylergometrine, has been observed. Similarly to the case of 2-bromo-LSD, MBL-61 was inactive as a psychedelic in humans at doses of up to 10 to 14 mg orally.
However, whereas 2-bromo-LSD can reportedly still produce some hallucinogenic effects at high doses, such effects are said to be completely lost in the case of MBL-61. In any case, both drugs are still potent serotonin receptor modulators like LSD, with MBL-61 having 5.3-fold the antiserotonergic activity of LSD in vitro and the highest degree of antiserotonergic activity of any other assessed lysergamide.
MBL-61 was first described in the scientific literature by Albert Hofmann and colleagues in 1957.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368193433 under CC BY-SA 4.0; modifications have been made.